Crinetics Pharmaceuticals (NASDAQ:CRNX) versus Xenetic Biosciences (NASDAQ:XBIO) Financial Contrast

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Xenetic Biosciences (NASDAQ:XBIO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Profitability

This table compares Crinetics Pharmaceuticals and Xenetic Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	N/A	-35.09%	-32.04%
Xenetic Biosciences	-110.42%	-64.66%	-54.63%

Volatility and Risk

Crinetics Pharmaceuticals has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.29, suggesting that its stock price is 129% more volatile than the S&P 500.

Earnings & Valuation

This table compares Crinetics Pharmaceuticals and Xenetic Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$1.54 million	3,050.76	-$298.41 million	($4.53)	-10.89
Xenetic Biosciences	$2.50 million	2.06	-$3.96 million	($2.05)	-1.10

Xenetic Biosciences has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Xenetic Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Crinetics Pharmaceuticals and Xenetic Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1	1	11	0	2.77
Xenetic Biosciences	1	1	0	0	1.50

Crinetics Pharmaceuticals presently has a consensus target price of $82.50, suggesting a potential upside of 67.17%. Given Crinetics Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Crinetics Pharmaceuticals is more favorable than Xenetic Biosciences.

Insider & Institutional Ownership

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are held by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Crinetics Pharmaceuticals beats Xenetic Biosciences on 8 of the 14 factors compared between the two stocks.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.